Fig. 1

Paroxetine ameliorates emotional dysfunction of APP/PS1 mice in the early age. a Relative expression of 5-HTergic receptors for AD patients compared with normal acquired from transcriptional analysis. b Heatmap of significant decreased 5-HTergic receptors. c Representative Immunofluorescence of serotonin in the prefrontal cortex and quantification of 3-month WT and APP/PS1 mice. n = 8. d Percent of time in center of open field test and total movement distance for each group for saline or paroxetine treated WT and APP/PS1 mice (Upper panel). Velocity and representative track map for each group (Down panel). n = 11–13. e The time spent in the open arms of elevated plus maze for saline or paroxetine treated WT and APP/PS1 mice. n = 11–13. f Immobility time of Forced-swim test for saline or paroxetine treated WT and APP/PS1 mice. n = 10. g Social index of Three-chamber test for saline or paroxetine treated WT and APP/PS1 mice. n = 7–8. Data are presented as mean ± SEM. *P < 0.05. ** P < 0.01; *** P < 0.001; **** P < 0.0001; two-way ANOVA with Sidak’s multiple comparison post hoc test (a, d, e, f, g) and unpaired t-test (c)